Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.

Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

Abstract: The present invention provides compounds having the Formula I The present invention also provides pharmaceutical compositions comprising a compound of Formula I and methods of treatment of atherosclerosis, obesity, restenosis, coronary heart disease, hyperlipoproteinemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: A process is provided for preparing a compound of the formula: using a compound having the formula wherein R2 and R3 are independently C1-C3 alkyl or phenyl.

Abstract: This invention relates to methods for treating bone loss in a mammal by administering to the mammal a therapeutically effective amount of leptin or a leptin mimetic. This invention also relates to methods for treating bone fracture, enhancing bone healing following facial reconstruction, maxillary reconstruction or madibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic growth and inducing vertebral synostosis by administering a therapeutically effective amount of leptin or a leptin mimetic. This invention further relates to methods and compositions comprising leptin or a leptin mimetic and estrogen, a selective estrogen receptor modulator or a bisphonate for treating the above-recited diseases and conditions.

Abstract: A process is provided for preparing a compound of the formula: comprising deprotecting a compound of the formula

Abstract: A rapidly-releasing and taste-masking pharmaceutical dosage form and a process for preparing such oral dosage form are disclosed.

Abstract: Compositions, especially in the form of tablets containing the polymorph II form of trovafloxacin mesylate, a lubricant, and microcrystalline cellulose (MC) as the diluent. Such compositions employing MC as a diluent exhibit good storage stability properties and dissolution.

Abstract: A process for preparing a tris-lactam crosslinking agent, tris-pyrrolidonyl triazine, from N,N',N"-tris(4-chlorobutyryl)melamine by treatment of the chlorobutyryl derivative with a base such as sodium or potassium carbonate to effect intramolecular cyclization to the tris-lactam. A curable composition comprised of tris-pyrrolidonyl triazine as the crosslinking agent and a hydroxyfunctional or aminofunctional material as a resin. Thick films with no pinholes are prepared from the curable compositions using powder coating techniques.

Abstract: A crosslinker composition based on a combination of 1,3,5-tris-(2-carboxyethyl)isocyanurate and a dicarboxylic acid crosslinking agent is provided. Also provided is a curable epoxy composition employing, as the crosslinker component, a combination of 1,3,5-tris-(2-carboxyethyl)isocyanurate and a dicarboxylic acid crosslinking agent, which curable composition finds use, for example, in coating applications.

Abstract: A process for preparing a tris-lactam crosslinking agent, tris-pyrrolidonyl triazine, from N,N',N"-tris(4-chlorobutyryl)melamine by treatment of the chlorobutyryl derivative with a base such as sodium or potassium carbonate to effect intramolecular cyclization to the tris-lactam. A curable composition comprised of tris-pyrrolidonyl triazine as the crosslinking agent and a hydroxyfunctional or aminofunctinoal material as a resin. Thick films with no pinholes are prepared from the curable compositions using powder coating techniques.

Abstract: Described is a liquid, partially alkoxymethylated melamine crosslinker composition having from about 2.6 to about 4.6 moles of combined formaldehyde per mole of melamine, from about 1.4 to about 4.4 moles of alkyl per mole of melamine, from about 1.3 to about 3.4 moles of NH per mole of melamine, a free formaldehyde level of less than about 0.5 weight percent based on 100 percent solids, and an N-methylol level of less than about 6.0 weight percent; processes for its preparation; a low formaldehyde emitting curable composition containing the crosslinker; as well as a method of coating a substrate and substrates so coated.

Abstract: Novel morpholino end-capped polyamino-1,3,5-triazines, methods for their use as light stabilizers for materials which are subject to degradation (for example, by actinic radiation), stabilizer compositions based on these morpholino end-capped polyamino-1,3,5-triazines and methods for their synthesis are herein described.

Abstract: At least bis-imido 1,3,5-triazines and processes of preparing the same are disclosed. Also disclosed are prepolymers having at least bis-imido functionality and curable compositions comprising at least bis-imido 1,3,5-triazines or prepolymers thereof in combination with active hydrogen and/or epoxy functional materials. The at least bis-imido 1,3,5-triazines and prepolymers may be advantageously employed as crosslinking agents which crosslink by a ring opening reaction that eliminates the release of volatile organic compounds.

Abstract: A non-yellowing one-package polyurethane coating composition containing an oxime-blocked polyisocyanate, an isocyanate-reactive material, and an imino-functional amino resin is provided. The coating composition is applied onto an acid-cured base coat and cured. The clear coat produced in this manner has good yellowness resistance and intercoat adhesion.Articles such as multi-layered coated substrates are prepared using the coating method of this invention. The coated substrates typically contain an acid-cured first layer and an adjacent layer derived from a curable composition containing an oxime-blocked polyisocyanate, an isocyanate-reactive material, and an imino-functional amino resin.

Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.